相关实验视频
Updated: Jan 13, 2026

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.1K
新兴的胰岛素类似物:一眼看看胰岛素类似物在不久的将来可能会如何看起来
Ntethelelo Sibiya1, Lorah Dzimwasha1, Samarah Zvandasara1
1Pharmacology Division, Faculty of Pharmacy, Rhodes University, Makhanda 6139, South Africa.
Pharmaceutics
|October 29, 2025
概括
新的胰岛素类似物正在开发中,以克服糖尿病管理的挑战. 这些创新重点是改善药物动力学特征和热稳定性,以改善患者的治疗结果.
科学领域:
- 生物技术是生物技术.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病管理面临当前胰岛素治疗的挑战.
- 过去的创新推动了寻找具有增强性能的理想胰岛素类似物.
- 生物技术和质工程的加速进步导致了新的胰岛素类似物.
研究的目的:
- 审查新型胰岛素模拟器设计和工程方面的最新进展.
- 更新科学和临床界关于胰岛素开发的尖端创新.
- 通过改进的胰岛素类似物来巩固糖尿病管理方面的进展.
主要方法:
- 新兴胰岛素类型的文献综述.
- 分析生物技术和类领域的设计和工程创新.
- 识别具有扩展的药理学特征和增加的热稳定性的胰岛素类似物.
主要成果:
- 在过去的十年中,许多胰岛素类似物已被报告,主要是在临床前研究中.
- 德格卢德克,Icodec和Efsitora是具有临床意义的例外.
- 新兴类型的药物表现出扩展的药理动力学,增强的热稳定性,对葡萄糖的反应性和肝脏偏好的活性.
结论:
- 胰岛素模拟设计的快速创新正在产生有希望的结果.
- 预计先进的胰岛素类别的进一步临床出现.
- 这些创新对于推进糖尿病管理至关重要.
相关概念视频
Insulin Formulations: Types and Delivery
642
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
642
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
Oral Hypoglycemic Agents: Sulfonylureas
765
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
765
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K

